Fluid biomarkers such as cerebrospinal fluid (CSF) YKL-40, soluble TREM2 (TREM2), and glial fibrillary acidic protein (GFAP) have been linked to different clinical stages of AD, offering potential tools for early diagnosis, disease monitoring, and prognosis (Kiraly et al., 2023b). This evidence concerns the gene GFAP and Alzheimer disease.